Advances in the Imaging of Pituitary Tumors
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
© 2020 Elsevier Inc. In most patients with pituitary adenomas magnetic resonance imaging (MRI) is essential to guide effective decision-making. T1- and T2-weighted sequences allow the majority of adenomas to be readily identified. Supplementary MR sequences (e.g. FLAIR; MR angiography) may also help inform surgery. However, in some patients MRI findings are ‘negative’ or equivocal (e.g. with failure to reliably identify a microadenoma or to distinguish postoperative change from residual/recurrent disease). Molecular imaging [e.g. 11C-methionine PET/CT coregistered with volumetric MRI (Met-PET/MRCR)] may allow accurate localisation of the site of de novo or persistent disease to guide definitive treatment (e.g. surgery or radiosurgery).
Description
Keywords
(11)C-methionine, MRI, Met-PET/MR(CR), PET/CT, Pituitary adenoma, Diagnostic Imaging, Endocrinology, Humans, Medical Oncology, Pituitary Neoplasms
Journal Title
Endocrinology and Metabolism Clinics of North America
Conference Name
Journal ISSN
0889-8529
1558-4410
1558-4410
Volume Title
Publisher
Elsevier